ANN ARBOR, Mich., Jan. 5, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V: ZOM), a veterinary pharmaceutical and health care solutions company, today announced it has entered into a research collaboration agreement with Celsee Diagnostics, Inc., an innovator of human health products in the emerging field of liquid biopsy. The research project defined in the agreement aims to test the feasibility of Celsee’s liquid biopsy technology for veterinary application as a canine cancer diagnostics.
A liquid biopsy is a blood test with the potential to detect the presence of circulating tumor cells in the blood. Circulating tumor cells, commonly referred to as CTCs, are cells that have shed from a primary tumor into neighboring blood vessels and are transported throughout the body’s circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy.
Concurrent to this research project, Zomedica filed a provisional application for patent with the United States Patent and Trademark Office (USPTO) in support of its research and development efforts specific to canine cancer diagnostics. The provisional patent is based on Zomedica’s identification of novel canine biomarkers for diagnosing canine cancers.
“Canine cancer is one of the most commonly diagnosed diseases in the veterinary clinic,” stated Zomedica’s Chief Medical Officer William MacArthur, MS, DVM. “It is difficult, expensive and often times impractical for veterinarians to diagnose some cancers in a non-invasive manner. As such, veterinarians are frequently required to make treatment recommendations to pet owners based on incomplete patient information.”
This translational opportunity aligns with Zomedica’s veterinary-focused mission to provide needs-driven solutions to the real-world problems of veterinary practice. Zomedica anticipates translational opportunities such as this to be an important component of its diversified product strategy.
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company targeting products for companion animals (canine, feline and equine) through a ground-breaking approach that focuses on the unmet needs of clinical veterinarians. Zomedica is building a diversified portfolio of products comprised of the discovery, development and commercialization of innovative drugs alongside novel drug delivery systems, devices and diagnostics. With multiple clinical veterinarians in executive management, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
About Celsee Diagnostics
Celsee Diagnostics, a privately-held Michigan-based company, develops automated systems for rare CTC enrichment and single-cell analysis. The company’s precise, accurate, and reliable platform for research and clinical diagnostics development will allow healthcare professionals more time to focus on their patients’ therapeutic treatment and outcomes. The label-free Celsee PREP platforms perform all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared slide automatically. Celsee’s SingleCell products provide access, efficiency and simplicity, the most desirable attributes related to products for use in single-cell isolation, analysis and retrieval.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact
Shameze Rampertab, CPA, CA
Barry Mire, Renmark Financial Communications Inc.
+1 416.644.2020 or +1 514.939.3989